4results about How to "Infection control" patented technology

The invention belongs to the field of medical instruments, and discloses a medical silica gel dressing fixing adhesive tape which comprises an adhesive tape body, and the adhesive tape body sequentially comprises a carrier layer, a silica gel adhesive layer and a stripping liner from outside to inside; the carrier layer is made of an elastic breathable material, and the silica gel adhesive layer is made of medical-grade organic silica gel; a plurality of first microcapsules are dispersed in the silica gel adhesive layer, the first microcapsules are drug-loaded microcapsules, and wall materials of the drug-loaded microcapsules are made of materials responding to the pH value, enzyme concentration or temperature change of a wound environment. Enzyme or ions are released after the second microcapsule is broken, the wall material of the first microcapsule is actively degraded, cascade response of'exudate increase-developing prompt-drug accelerated release 'is realized, a large amount of drugs are quickly released when the exudate appears, and infection or inflammation is effectively controlled.

The invention discloses application of morin, and relates to the technical field of bacterial quorum sensing inhibition. The invention discloses application of morin in preparation of a medicine for reducing enterotoxigenic escherichia coli quorum sensing. Quorum sensing of enterotoxigenic escherichia coli can be reduced by using 5.0 mg / mL of Morrin, so that secretion of virulence factors of the enterotoxigenic escherichia coli is reduced. In the Escherichia coli treated by the Morin, the Morin has no obvious inhibition effect on the growth of the Escherichia coli, and the abundance of an autoinducer 2 (AI-2) and a quorum sensing related gene is obviously reduced, so that the toxicity and the adhesion capability of the Escherichia coli are reduced. The method for reducing enterotoxigenic Escherichia coli quorum sensing provided by the invention is beneficial to replacing traditional antibiotic in-vivo treatment and assists in resisting bacterial infection.

The application discloses synthesis of a novel Schiff base gold (III) compound and antibacterial application thereof, and belongs to the technical field of medicine preparation; gold sodium aurothiomalate has significant antibacterial activity, but the Au-S bond thereof is easily broken by intracellular reducing thiol, and the gold sodium aurothiomalate is metabolized before reaching a target point to produce toxic side effects; based on the gold sodium aurothiomalate, developing a gold compound with stronger stability is one of strategies for overcoming drug-resistant bacteria; the Schiff base itself has antibacterial activity, and after being combined with gold (III) ions, the Schiff base can stabilize gold atoms and improve the activity of the gold atoms; in vitro antibacterial activity shows that Au6 and Au13 have significant antibacterial advantages on carbapenem and polymyxin-resistant Klebsiella pneumoniae, the minimum inhibitory concentration (MIC) is 10 micromoles, and the antibacterial activity is at least 16 times higher than that of the gold sodium aurothiomalate; in vivo antibacterial activity experiments prove that Au6 and Au13 can reduce mouse skin infection and promote wound healing, and can prolong the survival time of abdominal infection mice, and have important practical application value.